🔥 Final Overall Survival with Talazoparib + Enzalutamide as First-Line Treatment in Unselected Patients with #mCRPC in the Phase 3 TALAPRO-2 Trial #TALAPRO2 Confirms OS Benefit of Talazoparib + Enzalutamide in 1L mCRPC ✅ 45.8 vs. 37.0 months OS (HR 0.796, p = 0.0155) ✅ 33.1

💡Updated @Uroweb Guidelines on the Use of #Adjuvant Immune Checkpoint Inhibitors and #Subsequent Therapy for Renal Cell Carcinoma 👉 https://t.co/Zd7CYsvI8v @EUplatinum #JensBedke @Yasminabugh @AlbigesL @u_capitanio @DrDabestani @milanhoraplzen @Dr_Klatte #TeeleKuusk

Great opportunity to present on managing renal masses and Renal Cell Carcinoma in kidney transplant patients - at the Southside of Urology Symposium. Exploring challenges and approaches for this unique patient population.

💫🌟📢 Debate: To operate or not? Deferred cytoreductive nephrectomy in the ICI era🌟💫 👨‍⚕️ Axel Bex FOR YES & @PignotG FOR NO #RENALC24 @OncoAlert @mirrorsmed FOR YES: 🔎 Key Points: ➡️ Real-world data shows 17% underwent deferred CN with NIVO+IPI. ➡️ Median OS: 31.9 months

PEACE-1: Radiotherapy + abiraterone improves rPFS in low-volume de novo mCSPC but not OS. It reduces serious genitourinary events without increasing toxicity. A promising addition to standard care #ProstateCancer #Oncology #PEACE1 @OncoAlert @TheLancet @APCCC_Lugano

At #EMUC24, a clear split among attendees: some believe adjuvant pembrolizumab should be reserved only for the highest-risk RCC patients, while others support treating all KN-564 eligible. This underscores the urgent need for biomarkers to refine patient selection! @Uroweb

Incredible month at @UrologyMSK with @TouijerKarim—grateful for the shared knowledge and experience. The patient-centred approach truly makes a difference. Exciting to see game-changing results of extended lymphadenectomy trial on reducing PCa metastasis https://t.co/iZjYFV8ftc

Extended lymphadenectomy reduces metastasis in prostate cancer. Results of a large RCT are here! https://t.co/4myPFeOAeO @UrologyMSK @EUplatinum @Uroweb @CAU_URO #AUAMembers #aua #urology #ProstateCancer @VickersBiostats

Outcomes of Biopsy Grade Group 1 Prostate Cancer Diagnosis in the Danish Population by @HeinStroomberg et al Full article: https://t.co/LtmZslUBCF #UroSoMe #MedTwitter #EUO #PCa #ProstateCancer

🚨Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder Cancer🚨 👏Landmark trial in urology in @NEJM 😷592 patients randomized 🗓️Median f/u 6.1 years 👉No difference in... 5-year disease-free survival (60% v 56%) 5-year overall survival (63% v 59%)

History in the making: at #ERUS24 Prof @AlbertoBreda1 performs a partial nephrectomy from Bordeaux, France on a patient nearly 10,000km away in Beijing, China.

Successful ESRU meeting with urology residents from Europe and around the world! 🌍 We discussed in survey, education, and communication committees, with insightful talks and collaboration projects. Excited for the future of urology residency! #ESRU #Urology #eurep #eau #MedEd

Ever managed Apalutamide Rash? Have a look at this fresh new algorythm. More on: https://t.co/plo59FPojm

🚨 Urology residents! Share your "nightmare" cases at #EAU25 in Madrid! 🌟 Submit by Sept 10, 2024. Present & discuss with experts! 👩‍⚕️👨‍⚕️📅 📧 esrusecretary@gmail.com 📲 Scan the code in the image! 🗓️ March 21-24, 2025 📍 Madrid, Spain #ESRU @Uroweb @UrowebESU @EAUYAUrology

Siempre es un placer participar en lo Congresso Español de Urología 🇪🇸 y en compañía de los mejores 🇵🇹@JoseALPereira @vasco_quaresma @AnaJoaoGuerra Gracias a @InfoAeu e @ResidentesAEU por la hospitalidad 👏 🏝️ @apurologia @NIAPU_ @sutr_nesu

Una tarde muy productiva para nuestro grupo de residentes de Coimbra con 8 presentaciones en #AEU2024. Siempre es un placer participar en este gran congresso! @JoseALPereira @manuelmlopes @AnaJoaoGuerra @InfoAeu @apurologia @NIAPU_

Exciting #EAU24 #YUORDAY part 2 featured the Guidelines 🏆 Cup! @MariaJRibal & @JLVasquez82 moderated while finalists J. Devos (🇧🇪), J. Mendes Carvalho (🇵🇹), & M. Czerwaty (🇵🇱) competed fiercely! 💪 Congrats to the winner J. Mendes carvalho from Portugal! 🎉

Highlights from #EAU24 participation Friends, network, knowledge and fun in Paris 24

#EAU24 and my @ESRUrology meeting as a board member, so grateful with @eau_yuo and @Uroweb for all these amazing years! An experienced and highly motivated board will stay in charge of @ESRUrology and couldn’t be more proud! @Luca_Afferi @EnricoCheccucci @LoicBaekelandt

Immunotherapy-induced adverse events in metastatic renal cell carcinoma: A case of rapid response and complex challenges - ScienceDirect